Compare US Global Jets ETF (JETS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs State Street SPDR S&P Biotech ETF — how do they compare? US Global Jets ETF trades at $27.45 (market cap $878.48M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 11.5× US Global Jets ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| JETS | XBI | |
|---|---|---|
Market Cap | $878.48M | $10.11B |
Volume | 4,465,925 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $33.53 | $169.55 |
52-Week Low | $23.64 | $104.99 |
Typical Hold Time | 26 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS ETF trades at $27.45, down 0.8% with a bearish technical outlook as moving averages signal strong selling pressure. The fund faces headwinds from rising fuel costs and geopolitical tensions, while competitor aerospace/defense ETFs have outperformed. Recent news highlights airline earnings volatility and competitive pressure from alternative aviation investments.
The outlook remains challenging with fuel cost pressures and competitive ETF alternatives weighing on performance. Investment opportunity exists for contrarian investors given oversold RSI conditions, but risks from Middle East tensions and expense ratio disadvantages versus peers suggest cautious approach.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
